Leukemia Research
Volume 29, Issue 7 , Pages 739-748 , July 2005

Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid

Received 17 August 2004 ,Revised 18 November 2004 ,Accepted 19 November 2004.

References 

  1. Robertson KD, Wolffe AP. DNA methylation in health and disease. Nat Rev Genet. 2000;1:11–19
  2. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415–428
  3. Toyota M, Kopecky KJ, Toyota MO, Jair KW, Willman CL, Issa JP. Methylation profiling in acute myeloid leukemia. Blood. 2001;97:2823–2829
  4. Garcia-Manero G, Daniel J, Smith TL, Kornblau SM, Lee MS, Kantarjian HM, et al. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res. 2002;8:2217–2224
  5. Herman JG. Hypermethylation of tumor suppressor genes in cancer. Semin Cancer Biol. 1999;9:359–367
  6. Shen L, Toyota M, Kondo Y, Obata T, Daniel S, Pierce S, et al. Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood. 2003;101:4131–4136
  7. Hennessy BT, Garcia-Manero G, Kantarjian HM, Giles FJ. DNA methylation in haematological malignancies: the role of decitabine. Expert Opin Investig Drugs. 2003;12:1985–1993
  8. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G, Wijermans P, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine [decitabine] treatment. Blood. 2002;100:2957–2964
  9. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, et al. Phase I study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine [decitabine] in hematopoietic malignancies. Blood. 2004;103:1635–1640
  10. Rice JC, Allis CD. Code of silence. Nature. 2001;414:258–261
  11. Agalioti T, Chen G, Thanos D. Deciphering the transcriptional histone acetylation code for a human gene. Cell. 2002;111:381–392
  12. Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem. 2001;70:81–120
  13. Marks PA, Miller T, Richon VM. Histone deacetylases. Curr Opin Pharmacol. 2003;3:344–351
  14. Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol. 2001;13:477–483
  15. Johannessen CU, Johannessen SI. Valproate: past, present, and future. CNS Drug Rev. 2003;9:199–216
  16. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001;20:6969–6978
  17. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001;276:36734–36741
  18. Jones PL, Wolffe AP. Relationships between chromatin organization and DNA methylation in determining gene expression. Semin Cancer Biol. 1999;9:339–347
  19. Kondo Y, Shen L, Issa JP. Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biol. 2003;23:206–215
  20. Fahrner JA, Eguchi S, Herman JG, Baylin SB. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res. 2002;62:7213–7218
  21. Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 1997;25:2532–2534
  22. Rideout D, Chou T-C. Synergism, antagonism, and potentiation in chemotherapy: an overview. In:  Rideout D editors. Synergism and antagonism in chemotherapy. San Diego, California: Academic Press Inc.; 1991;p. 3–60
  23. Kikuchi T, Toyota M, Itoh F, Suzuki H, Obata T, Yamamoto H, et al. Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors. Oncogene. 2002;21:2741–2749
  24. Shen L, Kondo Y, Issa JP, Garcia-Manero G. Lack of p21[CIP1] DNA methylation in acute lymphocytic leukemia. Blood. 2002;100:3432–3433
  25. Ying J, Srivastava G, Gao Z, Zhang X, Murray P, Ambinder R, et al. Promoter hypermethylation of the cyclin-dependent kinase inhibitor [CDKI] gene p21WAF1/CIP1/SDI1 is rare in various lymphomas and carcinomas. Blood. 2004;103:743–746
  26. Garcia-Manero G, Jeha S, Daniel J, Williamson J, Albitar M, Kantarjian H, et al. Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia. Cancer. 2003;97:695–702
  27. Garcia-Manero G, Bueso-Ramos C, Daniel J, Williamson J, Kantarjian HM, Issa JP. DNA methylation patterns at relapse in adult acute lymphocytic leukemia. Clin Cancer Res. 2002;8:1897–1903
  28. Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase [HDAC] inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA. 2004;101:1241–1246
  29. Nguyen CT, Weisenberger DJ, Velicescu M, Gonzales FA, Lin JC, Liang G, et al. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine. Cancer Res. 2002;62:6456–6461

PII: S0145-2126(05)00038-X

doi: 10.1016/j.leukres.2004.11.022

Leukemia Research
Volume 29, Issue 7 , Pages 739-748 , July 2005

Article Tools

* Image Usage & Resolution